References
  1. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355(15):1572‐1582.
  2. Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014;32(12):1218–27.
  3. Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, et al. Chronic disease in the childhood cancer survivor study cohort: a review of published findings. J Clin Oncol 2009;27(14):2339–55.
  4. Meshref M, ElShazly N, Nasr M and AbdElhai R. Effect of different doses of prophylactic cranial irradiation in childhood lymphoblastic leukemia on CNS relapse, late cognitive decline and learning disabilities. journal of Cancer Therapeutics and Research 2013, 2:10.
  5. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol. 1999;17(7):2127‐2136.
  6. Casey DL, Kushner BH, Cheung N KV, Roberts SS, LaQuaglia MP, Wolden SL, et al. Reduced-dose radiation therapy to the primary site is effective for high-risk neuroblastoma: results from a prospective trial. Int J Radiat Oncol Biol Phys. 2019;104(2):409-414.
  7. Kahalley LS, Peterson R, Ris MD, Janzen L, Okcu MF, Grosshans DR, Ramaswamy V, et al. Superior Intellectual Outcomes After Proton Radiotherapy Compared with Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol. 2020;38:454-61.
  8. Eaton BR, Esiashvili N, Kim S, et al. Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro Oncol 2016;18:88;1–7.
  9. Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013;87:46–52.
  10. Sardaro A, Carbonara R, Petruzzelli MF, Turi B, Moschetta M, Scardapane A, et al. Proton therapy in the most common pediatric non-central nervous system malignancies: an overview of clinical and dosimetric outcomes. Ital J Pediatr 2019;45(1):170.
  11. Yock TI, Bhat S, Szymonifka J, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol 2014;113:89–94.
  12. Breneman JC, Donaldson SS, Constine L, Merchant T, Marcus K, Paulino A, et al. The Children’s Oncology Group Radiation Oncology Discipline: 15 Years of Contribution to the Treatment of Childhood Cancer. Int J Radiat Oncol Biol Phys 2018;101(4):860-874.
  13. Weber DC, Habrand JL, Hoppe BS, Kayser CH, Laack NN, Langendijk JA, et al. Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiother Oncol . 2018;128(1):44‐55.
  14. Indelicato D, Merchant T, Leperriere N, Lassen Y, Vennarini S, Wolden S, et al. Consensus report from the Stockholm pediatric proton therapy conference. Int J Radiat Oncol Biol Phys 2016;96(2):387-392.
  15. Tonse R, Noufal MP, Deopujari CE, Jalali R. India’s first proton beam therapy pediatric patient. Neurol India 2020;68(1):189-191.
  16. Tonse R, Chilukuri S, Shamurailatpam D, Jalali R. Introduction of image guided pencil beam scanning proton therapy for skull base tumors in India: A report of two cases and a brief review of literature. Neurol India 2020;68(1):42-44.
  17. Chilukuri S, Jalali R, Panda PK. Survey on variations of knowledge and perception amongst radiation oncologists across India regarding proton beam therapy. Int J Particle Therapy 2020;6(4):PTC58-0527.
  18. Odei B, Frandsen JE, Boothe D, Ermoian RP, Poppe MM. Patterns of Care in Proton radiation therapy for pediatric central nervous system malignancies. Int J Radiat Oncol Biol Phys 2017;97(1):60–3.
  19. Hess CB, Indelicato DJ, Paulino AC, Hartsell WF, Hill-Kayser CE, Perkins SM, et al. An update from the Pediatric Proton Consortium Registry. Front Oncol 2018;8:165.
  20. Carbonara R, Di Rito A, Monti A, Rubini G, Sardaro A. Proton versus photon radiotherapy for pediatric central nervous system malignancies: A systematic review and meta-Analysis of dosimetric comparison studies. J Oncol 2019:5879723.
  21. Yock TI, Yeap BY, Ebb DH, Weyman E, Eaton BR, Sherry NA, et al. Long‐term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single‐arm study. Lancet Oncol. 2016;17:287‐ 298.
  22. Cotter SE, Herrup DA, Friedmann A, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011;81:1367–73.
  23. Jalali R, Gupta T, Goda JS, Goswami S, Shah N, Dutta D, et al. Efficacy of stereotactic conformal radiotherapy vs conventional radiotherapy on benign and low-grade brain tumors: a Randomized clinical trial. JAMA Oncol 2017;3(10)1368-1376.
  24. Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy.  Variations as function of biological endpoint, dose, and linear energy transfer. Phys Med Biol 2014;59(22):R419-72.
  25. Ladra MM, Szymonifka JD, Mahajan A, Friedmann AM, Yeap BY, Goebel CP, et al. Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.J Clin Oncol 2014;32(33):3762‐3770.
  26. Suneja G, Poorvu PD, Hill-Kayser C, Lustig RA. Acute toxicity of proton beam radiation for pediatric central nervous system malignancies. Pediatr Blood Cancer 2013;60(9):1431–6.
  27. Selo N, Bölling T, Ernst I, Pape H, Martini C, Rübe C, et al. Acute toxicity profile of radiotherapy in 690 children and adolescents: RiSK data. Radiother Oncol 2010;97(1):119–26.
  28. Song S, Park HJ, Yoon JH, et al. Proton beam therapy reduces the incidence of acute haematological and gastrointestinal toxicities associated with craniospinal irradiation in pediatric brain tumors. Acta Oncol 2014;53:1158–64.
  29. Bujold A, Craig T, Jaffray D, Dawson LA. Image-guided radiotherapy: Has it influenced patient outcomes? Semin Radiat Oncol 2012;22:50-61.
  30. Alcorn SR, Chen MJ, Claude L,Dieckmann K, Ermoian RP,Ford EC, et al. Practice patterns of photon and proton pediatric image guided radiation treatment: results from an International Pediatric Research consortium. Pract Radiat Oncol . 2014;4(5):336‐341.
  31. Three Year Report of the Population Based Cancer Registries 2012-2014: Report of 27 PBCRs; National Cancer Registry Programme, Indian Council Medical Research, Bangalore. 2016.
  32. Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol 2005;44(8):850‐861.
  33. Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 2005;103(4):793–801.
  34. Mailhot Vega R, Kim J, Hollander A, et al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer 2015;121:1694–702.
  35. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer 2016;122(10):1483–501.
  36. Noticewala SS, Williamson CW, Murphy JD. Cost-effectiveness of proton therapy for parameningeal rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2016;96(2)supplement:e398.
  37. Chilukuri S, Panda PK, Jalali R. PITChing(professional organizations, innovative clinical trial design and collaborative approach) for evidence generation for proton therapy. RadiatOncol2020;15:138 https://doi.org/10.1186/s13014-020-01538-y
KEY WORDS: proton beam therapy, demography, acute toxicities, children, adolescent